Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATHER1: Zimura in Geographic Atrophy Secondary to Dry AMD
NCT02686658Phase 3Completed
- Sponsor
- IVERIC bio
- Start
- Dec 2015
- Primary completion
- Sep 2019
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of avacincaptad pegol in geographic atrophy (GA) (6 arms), sponsored by IVERIC bio. Primary endpoint: Change From Baseline in Geographic Atrophy Area as Measured by Fundus Autofluorescence at 12 months. Started Dec 2015; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02686658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686658.